Regulation of CCN2 by CCN3 and its therapeutic and diagnostic potential in fibrosis, sclerosis and other diseases
US7780949B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Jan 10, 2006 |
| Grant date | Aug 24, 2010 |
| Priority date | — |
| Expiry date | Oct 14, 2026 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/347
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention discloses a role of CCN3 in diseases associated with the overexpression of CCN2, which include but are not limited to kidney disease, fibrosis, and cancer. The full length CCN3 protein or fragments thereof or isoforms (or combinations) of CCN3 are involved in these diseases. The isolated and purified CCN3 protein or its fragments or isoforms (or combinations) of CCN3 can be potentially used in the treatment or prevention of these diseases by regulating the expression and/or activity of the CCN2 protein. The level of CCN3 in tissue or body fluids can also be used to predict, diagnose and/or follow the progression of diseases as well as to determine the effectiveness of therapeutic intervention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.